Clinical trialNCT00399789CompletedPhase 1/PHASE2Interventional

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

SponsorAEterna ZentarisEnrollment121Non Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David Spigel, MD
SCRI Development Innovations, LLC
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Aoi Pharmaceuticals Investigative Site
Tucson, Arizona, United States
Aoi Pharmaceuticals Investigative Site
Pomona, California, United States
Aoi Pharmaceuticals Investigative Site
Aventura, Florida, United States
Aoi Pharmaceuticals Investigative Site
Hollywood, Florida, United States
Aoi Pharmaceuticals Investigative Site
Lakeland, Florida, United States
Aoi Pharmaceuticals Investigative Site
Ormond Beach, Florida, United States
Aoi Pharmaceuticals Investigative Site
Lawrenceville, Georgia, United States
Aoi Pharmaceuticals Investigative Site
Galesburg, Illinois, United States
Aoi Pharmaceuticals Investigative Site
New Albany, Indiana, United States
Aoi Pharmaceuticals Investigative Site
Grand Rapids, Michigan, United States
Aoi Pharmaceuticals Investigative Site
Kalamazoo, Michigan, United States
Aoi Pharmaceuticals Investigative Site
Billings, Montana, United States
Aoi Pharmaceuticals Investigative Site
Albuquerque, New Mexico, United States
Aoi Pharmaceuticals Investigative Site
Albany, New York, United States
Aoi Pharmaceuticals Investigative Site
Armonk, New York, United States
Aoi Pharmaceuticals Investigative Site
Greenville, South Carolina, United States
Aoi Pharmaceuticals Investigative Site
Chattanooga, Tennessee, United States
Aoi Pharmaceuticals Investigative Site
Nashville, Tennessee, United States
Aoi Pharmaceuticals Investigative Site
Dallas, Texas, United States
Aoi Pharmaceuticals Investigative Site
Dallas, Texas, United States
Aoi Pharmaceuticals Investigative Site
Tyler, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Perifosine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2004
Primary completion: 31 Dec 2010
Completion: 31 Dec 2011
Last update posted: 22 Feb 2018
Registered enrollment: 121
Registry id: NCT00399789

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.